Texas Retina Associates
Welcome,         Profile    Billing    Logout  
 5 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Schefler, Amy C
AL, NCT05844982: Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 Mg) Intravitreal Implants Vs Observation for Prevention of VA Loss Due to Radiation Retinopathy

Recruiting
3
600
US
Faricimab, fluocinolone acetonide
Jaeb Center for Health Research, National Eye Institute (NEI), National Institutes of Health (NIH), Alimera Sciences, Genentech, Inc.
Radiation Retinopathy, Visual Impairment
12/29
12/29
NCT03085784: Intravitreal Aflibercept Injection for Radiation Retinopathy Trial

Active, not recruiting
2
40
US
Aflibercept, Eylea
Amy C Schefler, MD, Regeneron Pharmaceuticals
Radiation Retinopathy
10/21
10/21
NCT01925599: BAP1 Testing in Instance Choroidal Nevi or Uveal Melanoma

Active, not recruiting
N/A
133
US
Amy C Schefler, MD
Choroidal Nevi, Uveal Melanoma
01/22
01/22
NCT05266430: Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

Terminated
N/A
2
US
Standard of Care, AU-011, belzupacap sarotalocan, bel-sar
Aura Biosciences
Choroidal Melanoma, Indeterminate Lesions
02/23
04/23
Shami, Michel
AL, NCT05844982: Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 Mg) Intravitreal Implants Vs Observation for Prevention of VA Loss Due to Radiation Retinopathy

Recruiting
3
600
US
Faricimab, fluocinolone acetonide
Jaeb Center for Health Research, National Eye Institute (NEI), National Institutes of Health (NIH), Alimera Sciences, Genentech, Inc.
Radiation Retinopathy, Visual Impairment
12/29
12/29
AO, NCT05904028: Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

Recruiting
3
600
Canada, US
Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule, Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule, Home OCT
Jaeb Center for Health Research, National Institutes of Health (NIH), National Eye Institute (NEI), Juvenile Diabetes Research Foundation
Neovascular Age-related Macular Degeneration
07/27
07/27
Protocol AF, NCT04661358: Fenofibrate for Prevention of DR Worsening

Recruiting
3
560
US
Fenofibrate, Placebo
Jaeb Center for Health Research, National Institutes of Health (NIH), National Eye Institute (NEI), Juvenile Diabetes Research Foundation, Roche Pharma AG, The Leona M. and Harry B. Helmsley Charitable Trust
Diabetic Retinopathy
04/29
04/29
AN, NCT05727891: Evaluation of Tonabersat for DME

Active, not recruiting
2
128
US
Tonabersat, Placebo
Jaeb Center for Health Research, National Institutes of Health (NIH), National Eye Institute (NEI), Juvenile Diabetes Research Foundation
Diabetic Macular Edema
06/25
11/25
ROP4, NCT04634578: Bevacizumab Treatment For Type 1 ROP

Recruiting
2
80
Canada, US
Bevacizumab, Avastin
Jaeb Center for Health Research, Pediatric Eye Disease Investigator Group, National Eye Institute (NEI)
Retinopathy of Prematurity
07/25
07/27
Protocol AM, NCT05145491: Randomized Trial Comparing Immediate Vs. Deferred Surgery for Symptomatic ERM

Recruiting
N/A
400
US
Immediate Vitrectomy, Deferred Vitrectomy
Jaeb Center for Health Research, National Institutes of Health (NIH), National Eye Institute (NEI), Juvenile Diabetes Research Foundation
Epiretinal Membrane
12/26
12/26
McGregor, Mary Lou
ROP4, NCT04634578: Bevacizumab Treatment For Type 1 ROP

Recruiting
2
80
Canada, US
Bevacizumab, Avastin
Jaeb Center for Health Research, Pediatric Eye Disease Investigator Group, National Eye Institute (NEI)
Retinopathy of Prematurity
07/25
07/27

Download Options